OPEC+ Opens The Taps: Midstream's Moment
OPEC+ has decided to maintain its policy of gradually increasing oil production to meet rising global demand. This creates an investment opportunity in companies that provide the essential midstream services, such as transportation and storage, which will see increased business from the higher oil supply.
Your Basket's Financial Footprint
Basket market capitalisation summary and investor takeaways for a midstream-focused basket dominated by large-cap names.
- Large-cap concentration tends to lower volatility, offering more stable returns and closer tracking of broader markets.
- Suitable as a core holding for diversified portfolios, not a high-risk speculative allocation.
- Likely to deliver steady, long-term value rather than rapid, short-term explosive gains.
WES: $15.34B
HESM: $6.98B
WMB: $76.13B
- Other
About This Group of Stocks
Our Expert Thinking
OPEC+ is maintaining its gradual oil production increases to meet rising global demand. This creates a steady flow of crude that needs to be transported, stored, and processed through critical infrastructure. Companies that own pipelines, storage terminals, and tanker fleets generate revenue from the volume they handle, making them direct beneficiaries of higher oil throughput.
What You Need to Know
These midstream companies operate essential infrastructure that's independent of oil price swings. They make money from the volume of oil moving through their systems, not the commodity price itself. This creates a more predictable revenue stream during periods of supply certainty, making this sector particularly attractive when production volumes are increasing.
Why These Stocks
Each company in this group was handpicked for their strategic position in the oil supply chain. They own critical infrastructure like pipelines, storage facilities, and transportation assets that become more valuable as oil volumes increase. Professional analysts selected these stocks based on their ability to capture increased business from OPEC+'s production strategy.
Why You'll Want to Watch These Stocks
Volume Surge Ahead
OPEC+ is opening the taps with steady production increases, creating more oil that needs to flow through pipelines and storage facilities. These companies get paid for every barrel that moves through their infrastructure.
Infrastructure Goldmine
While oil prices go up and down, these companies own the essential pipes, terminals, and transport systems that oil must use. More production means more business, regardless of commodity price swings.
Dividend Powerhouses
Many midstream companies are known for attractive dividend yields, supported by steady cash flows from long-term contracts. Higher volumes could mean even stronger payouts to shareholders.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Tech Stocks (AI Valuation Reset) Present Potential Entry
Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.
Walmart Succession Plan Explained | Market Effects
Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.